Latest market price
20.03
+0.02+0.10%
OverviewShort InterestFilings
BLCOQT80Bausch + Lomb Corporation·NYSE
20.03+0.10%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TFX-0.51%$139.95ATR-1.08%$142.31STVN-28.57%$14.10MMSI-0.18%$84.16AVTR-0.13%$15.59RGEN+3.08%$178.27COO-0.77%$60.83BAX+5.24%$25.49
Snapshot
Index—P/E—EPS (ttm)-0.31Insider Own—Shs Outstand357.50MPerf Week13.68%
Market Cap7.15BForward P/E17.02EPS next Y1.18Insider Trans-0.06%Shs Float45.69MPerf Month16.66%
Enterprise Value11.74BPEG—EPS next Q0.35Short Float5.56%Perf Quarter19.51%
Income-111.00MP/S1.32EPS this Y73.87%Short Ratio5.65Perf Half Y25.19%
Sales5.41BP/B1.10EPS next Y27.79%ROA-0.80%Short Interest2.54MPerf YTD17.27%
Book/sh18.21P/C13.94EPS next 5Y30.03%ROE-1.73%52W High21.36 -6.23%Perf Year34.07%
Cash/sh1.44P/FCF28.16EPS past 3/5Y—ROIC3.78%52W Low14.44 38.71%Perf 3Y26.93%
Dividend Est.—EV/EBITDA17.11Sales past 3/5Y10.62% 8.38%Gross Margin58.62%Volatility5.14% 3.56%Perf 5Y—
Dividend TTM—EV/Sales2.17EPS Y/Y TTM—Oper. Margin8.41%ATR (14)0.68Perf 10Y—
Dividend Ex-Date—Quick Ratio1.04Sales Y/Y TTM8.78%Profit Margin-2.05%RSI (14)74.02Recom2.65
Dividend Gr. 3/5Y—Current Ratio1.56EPS Q/Q88.89%SMA2013.00%Beta0.97Target Price21.50
Payout0.00%Debt/Eq0.78Sales Q/Q7.34%SMA5014.72%Rel Volume1.17Prev Close20.01
Employees13,000LT Debt/Eq0.78EarningsFeb 17SMA20019.94%Avg Volume582.97KPrice20.03
IPO DateMay 06, 2022Option/ShortYes / YesEPS/Sales Surpr.58.54% 0.21%Net Debt/EBITDA6.68Volume682,329Change0.10%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-02-26DowngradeHC Wainwright & Co.Buy → Neutral
Oct-29-26ReiteratedDeutsche BankHold$16 → $20
Oct-06-26InitiatedBarclaysOverweight$20 → $24
Sep-09-26InitiatedLeerinkOutperform$24
Aug-03-26ReiteratedHC Wainwright & Co.Buy$20 → $21
Jul-30-26ReiteratedUBSBuy$21 → $23
Jul-28-26InitiatedUBSBuy$21
Jul-06-26ReiteratedEvercore ISI GroupIn Line$18 → $17
Apr-30-26ReiteratedDeutsche BankHold$18 → $16
Feb-23-26ReiteratedHC Wainwright & Co.Buy$17 → $20
Latest News· Times ET
Today
Today12:41PM
BLCO vs. HQY: Which Stock Is the Better Value Option?zacks.com
Nov-02-26
Nov-02-2611:01AM
Best Momentum Stock to Buy for November 2ndzacks.com
10:41AM
Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Termzacks.com
07:36AM
New Strong Buy Stocks for November 2ndzacks.com
Oct-29-26
Oct-29-2607:00AM
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Educationbusinesswire.com
06:03AM
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19Benzinga
02:05AM
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Callmarketbeat.com
Oct-28-26
Oct-28-2601:39PM
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcriptseekingalpha.com
09:36AM
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimateszacks.com
06:58AM
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidancebusinesswire.com
Oct-22-26
Oct-22-2607:00AM
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-UpYahoo
Oct-16-26
Oct-16-2612:27PM
3 Reasons BLCO is Risky and 1 Stock to Buy InsteadYahoo
Oct-12-26
Oct-12-2612:03PM
Bausch + Lomb (NYSE:BLCO) Shares Down 5.8% – What’s Next?defenseworld.net
10:13AM
Why Is Bausch + Lomb Stock Falling Monday?Benzinga
06:45AM
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidancebusinesswire.com
Company

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue5,4135,1014,7914,146—————
Cost of Goods Sold Incl. D&A2,2402,3081,8721,642—————
Gross Profit3,1732,7932,9192,504—————
Selling, General and Administrative Excl. Other2,2522,2342,0821,736—————
Research and Development400371343324—————
Other Operating Expense660332314—————
Operating Income455188162130—————
Interest Expense388431399283—————
Unusual Expense
—————————
Non-Operating Income (Expense)-71-743-13—————
Net Income Before Taxes-4-317-234-166—————
Income Taxes99357182—————
Consolidated Net Income-111-360-317-260—————
Net Income From Continuing Operations-103-352-305-248—————
Net Income-111-360-317-260—————
EPS (Recurring)-0.31-1.02-0.90-0.74—————
EPS (Basic, Before Extraordinaries)-0.31-1.02-0.90-0.74—————
EPS (Diluted)-0.31-1.02-0.90-0.74—————
EBITDA686535601499—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio1.321.191.331.44—————
Gross Margin58.6254.7560.9360.40—————
Operating Margin8.413.693.383.14—————
Net Margin-2.05-7.06-6.62-6.27—————
Shares Outstanding358354352351—————
Market Capitalization7,1716,0466,3575,988—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$21.31$19.34$17.36$15.38$13.41● Close Price0.00M0.57M1.15M1.72M2.29MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Munsch FrederickSVP, Controller and CAOOct 29 '26Sale20.48112,0152,294,06745,831Nov 02
Munsch FrederickSVP, Controller and CAOOct 29 '26Option Exercise17.99112,0152,015,306157,846Nov 02
Munsch FrederickSVP, Controller and CAOAug 10 '26Sale16.7852,900887,66245,831Aug 12
VON ESCHENBACH ANDREW C.DirectorAug 07 '26Sale16.586,059100,45863,733Aug 10
VON ESCHENBACH ANDREW C.DirectorAug 06 '26Sale16.5012,500206,25069,792Aug 10
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23
SAUNDERS BRENT LCEO and Chairman of the BoardMay 22 '25Buy11.2822,000248,072719,156May 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.